# US 2026/0086083 A1 · Human In Vitro Cardiotoxicity Model

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0086083 A1
- Document ID: US20260086083A1
- Status: Published application
- Kind: A1
- Application number: 19/338,399
- Filed: 2025-09-24
- Published: 2026-03-26
- Earliest claimed: 2019-05-16
- Assignees: Brown University; Rhode Island Hospital
- Applicants: Brown University; Rhode Island Hospital
- Inventors: Kareen L. K. Coulombe; Cassady E. Rupert; Celinda M. Kofron; Bum-Rak Choi; Taeyun Kim; Ulrike Mende
- Web page: https://patentgrep.com/patent/US20260086083A1

## CPC

- G01N 33/5073: {Stem cells}
- G01N 33/5088: {of vertebrates}
- C12N 5/0697: {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N5/0691)}
- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 21/6456: {Spatial resolved fluorescence measurements; Imaging}
- G01N 33/5014: {for testing toxicity}
- G01N 33/5044: {involving specific cell types}
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- G06T 7/0012: {Biomedical image inspection}
- G01N 2021/6439: {with indicators, stains, dyes, tags, labels, marks}
- G01N 2800/32: Cardiovascular disorders
- G06T 2207/10064: Fluorescence image
- G06T 2207/30024: Cell structures in vitro; Tissue sections in vitro
- G06T 2207/30048: Heart; Cardiac
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL

## Abstract

The Cardio-Tox Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

## Claims

### Claim 1

An in vitro model for arrhythmogenic cardiotoxicity, comprising:
(a) human pluripotent stem cell-derived cardiomyocytes; and
(b) human cardiac fibroblasts,
in three-dimensional self-assembled microtissues.

### Claim 2 (depends on 1)

The in vitro model of claim 1, wherein the model consists essentially of about 5% human cardiac fibroblasts.

### Claim 3 (depends on 1)

A method of making the in vitro model of claim 1, comprising the steps of:
(1) obtaining separate samples of cell-cultured human pluripotent stem cell-derived cardiomyocytes and cell-cultured human cardiac fibroblasts;
(2) mixing the cell-cultured human pluripotent stem cell-derived cardiomyocytes and the cell-cultured human cardiac fibroblasts in defined ratios;
(3) pipetting the mixed cells into molds for forming microtissues;
(4) allowing the mixed cells to settle into microtissue recesses in the molds;
(5) culturing the mixed cells overnight to allow microtissues to form, wherein the cells of the microtissues are connected through adhesion junctions and functional junctions; and
(6) culturing the microtissues with electrical stimulation for 1 week and up to several weeks, sometimes in the presence of a chemical compound at a range of concentrations, until the time of use for cardiotoxicity assessment.

### Claim 4 (depends on 1)

A method of using the in vitro model of claim 1 to screen compounds for arrhythmogenic cardiotoxicity, comprising the steps of:
(1) loading a voltage- or calcium-sensitive dye into the microtissues in culture;
(2) sequentially exposing the microtissues to chemicals for short time (5-30 minutes) assessing acute responses or maintaining exposure to chemicals used during the culture period for chronic exposure assessment;
(3) collecting fluorescent and/or bright field images with high speed, high resolution cameras; and
(4) automatically analyzing fluorescent imaging data to reduce bias, increase reliability, and increase throughput with new multiple optimized algorithms and check points for the action potentials and calcium transients of cardiac microtissues.
